<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Female Troubles</title>
    <meta content="LTR131547" name="slug"/>
    <meta content="22" name="publication_day_of_month"/>
    <meta content="10" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Sunday" name="publication_day_of_week"/>
    <meta content="Magazine Desk" name="dsk"/>
    <meta content="18" name="print_page_number"/>
    <meta content="6" name="print_section"/>
    <meta content="5" name="print_column"/>
    <meta content="Magazine; Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="1240648"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Features/Magazine</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20001022T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9405E3D61E3FF931A15753C1A9669C8B63" item-length="94" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Female Troubles</hl1>
      </hedline>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Peter D. Kramer's acute analysis of Prozac and Sarafem (The Way We Live Now, Oct. 1) omitted a key point. Prozac's release was not only a pharmacological advance but an important step toward destigmatizing depression. The success of Prozac (and of Kramer's book ''Listening to Prozac'') gave depression more public acceptability. Eli Lilly's cynical repackaging of Prozac as Sarafem for PMS threatens to have the opposite effect: it's Prozac for people who fear taking a psychotropic medication for their mood problems.</p>
        <p>John C. Markowitz, M.D.  New York</p>
      </block>
      <block class="full_text">
        <p>Peter D. Kramer's acute analysis of Prozac and Sarafem (The Way We Live Now, Oct. 1) omitted a key point. Prozac's release was not only a pharmacological advance but an important step toward destigmatizing depression. The success of Prozac (and of Kramer's book ''Listening to Prozac'') gave depression more public acceptability. Eli Lilly's cynical repackaging of Prozac as Sarafem for PMS threatens to have the opposite effect: it's Prozac for people who fear taking a psychotropic medication for their mood problems.</p>
        <p>John C. Markowitz, M.D.  New York</p>
      </block>
    </body.content>
  </body>
</nitf>
